RESUMO
OBJECTIVE: To evaluate the implementation of Xpert-MTB/RIF®, as an early diagnosis technique, in a rural area of Ethiopia. METHODS: Data were retrospectively collected from those patients over 13 years of age who were requested to take the Xpert MTB/RIF® test in a rural hospital located 45 km from the reference laboratory, during the first 3 years of its implementation (2015, April -2018, April). RESULTS: A total of 306 patients older than 13 years were evaluated, in 85 (27.8%) there was an error in the processing of the test and the result was not obtained. Of the 221 samples with results, the median time between obtaining the sample and receiving the result was 21 days and 42 of them were positive (19%, 95% CI: 14.2-24.9%). The sample with the highest diagnostic yield was adenopathy (88.8%; [8/9]; p<0.001). CONCLUSIONS: There are more bacteriological diagnoses with Xpert-MTB/RIF®, but with a delay in obtaining the result and its main objective, which is early diagnosis, is not achieved.
Assuntos
Mycobacterium tuberculosis , Tuberculose Pulmonar , Tuberculose , Humanos , Pré-Escolar , Tuberculose Pulmonar/diagnóstico , Hospitais Rurais , Estudos Retrospectivos , Etiópia/epidemiologia , Sensibilidade e Especificidade , Tuberculose/diagnóstico , Tuberculose/epidemiologia , EscarroAssuntos
COVID-19/genética , Gravidade do Paciente , Receptores Androgênicos/genética , Idoso , Variação Genética , Humanos , Unidades de Terapia Intensiva , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Admissão do Paciente , Peptídeos/genética , Estudos Prospectivos , SARS-CoV-2 , Análise de Sequência de DNAAssuntos
Antagonistas de Androgênios/uso terapêutico , COVID-19 , Admissão do Paciente , Idoso , Idoso de 80 Anos ou mais , Dutasterida/uso terapêutico , Finasterida/uso terapêutico , Humanos , Unidades de Terapia Intensiva , Masculino , Pessoa de Meia-Idade , Estudos Observacionais como Assunto , Estudos Prospectivos , SARS-CoV-2 , Espironolactona/uso terapêuticoRESUMO
Helminth infections cause considerable morbidity worldwide and may be frequently underdiagnosed especially in areas of lower endemicity. Patients may harbor latent infections that may become symptomatic years or decades after the initial exposure and timely diagnosis may be critical to prevent complications and improve outcomes. In this context, disease in special populations, such as immunosuppressed patients, may be of particular concern. Heightened awareness and recent diagnostic developments may contribute to the correct management of helminth infections in nonendemic regions. A review of the main helminth infections in travelers and migrants (strongyloidiasis, taeniasis-neurocysticercosis and schistosomiasis) is presented, focusing on epidemiology, developments in diagnosis, treatment and prevention.